Engflag

Cenital

Quick links to important sections

Cenital

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cenital

What is Cenital? An Overview

Property Description
Active ingredient Aceclofenac
Form Oral Tablet
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and inflammation
Origin Synthetic (chemically produced)

What Type of Medicine is Cenital?

Cenital is the name for a medicine containing the active substance Aceclofenac, which belongs to a major group of drugs called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This classification means the medicine is designed to reduce both pain and inflammation throughout the body.

Aceclofenac is a synthetic compound, chemically manufactured rather than directly derived from natural sources, and is related to other established NSAIDs. Pharmacological studies clinically recognize Aceclofenac for its strong anti-inflammatory properties, often making it a preferred choice for persistent musculoskeletal discomfort. This analysis suggests the medicine is designed to effectively manage inflammatory symptoms.

Composition and General Purpose

Cenital is typically a single-active ingredient product supplied as an oral tablet. This simple composition ensures that the sole active drug, Aceclofenac, is absorbed through the digestive system to provide systemic action—meaning its therapeutic effect is distributed throughout the body.

The primary function of this drug is to provide symptomatic relief by interfering with the body's natural processes that create inflammation, such as those that produce prostaglandins. Its role is clinically recognized in easing discomfort commonly associated with conditions causing chronic inflammation. The oral route offers a convenient method for achieving internal relief from stiffness and pain associated with inflammatory conditions.

What side effects are possible with Cenital?

Possible side effects and safety information

The safety characteristics of Cenital (Aceclofenac) are detailed in official regulatory documents, which classify adverse reactions primarily by incidence and the affected physiological system.

Adverse Reaction Classification

Side effects are categorized by frequency, with Common reactions (ge 1/100 to <1/10) including gastrointestinal effects such as dyspepsia, abdominal pain, nausea, and diarrhoea, alongside dizziness and increases in liver enzyme levels. Reactions classified as Uncommon (ge 1/1,000 to <1/100) include flatulence, gastritis, rash, and pruritus. Rare reactions (ge 1/10,000 to <1/1,000) documented in the labeling include anaphylactic reaction and visual disturbance.

Serious Adverse Reactions and Safety Constraints

The official safety profile highlights the risk of several serious adverse reactions. These include serious gastrointestinal complications, such as haemorrhage, ulceration, and perforation. The labeling also contains a warning regarding the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. Rare but severe hypersensitivity responses, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.

Specific safety statements are tied to the timing of use; for example, the risk of serious gastrointestinal events is higher during the initial stages of treatment, while cardiovascular risk may increase with the duration of exposure. Use is officially restricted, or contraindicated, for individuals with active or a history of recurrent peptic ulcer/haemorrhage, and for those with severe heart, renal, or hepatic failure. Furthermore, older adults are specifically noted in regulatory text to have an increased frequency and risk of serious adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents specify that the ingestion of Cenital (Aceclofenac) in quantities exceeding the therapeutic range may lead to documented clinical signs. Manifestations of overdose can include gastrointestinal symptoms such as nausea, vomiting, epigastric pain, and the potential for gastrointestinal bleeding. Central nervous system effects may present as headache, dizziness, drowsiness, fainting, and occasionally convulsions. Systemic signs documented include hypotension and respiratory depression.

Required Emergency Action

Urgent medical attention is necessary if a potentially life-threatening overdose is suspected or if severe signs, such as fainting or prolonged convulsions, are observed. These situations require immediate contact with emergency medical services, as the severity of outcomes can escalate quickly.

Official Management and Monitoring

In cases of documented poisoning, treatment is symptomatic and supportive. Time-critical procedures, such as the consideration of activated charcoal or gastric lavage (in adults), are advised within one hour of ingestion of a potentially toxic amount. For significant poisoning, regulatory information acknowledges the possibility of acute renal failure and liver damage. Therefore, close monitoring of renal function and liver function is mandated during management. There is no specific antidote listed in the official prescribing information for Cenital overdose.

Therapeutic Uses of Cenital

What Cenital Treats: Main Uses and Benefits

Cenital is commonly used to help with the symptomatic relief of chronic inflammatory joint diseases, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is applied across domains where additional symptomatic support is needed to address symptom clusters that create noticeable physiological strain. The medication is considered relevant for easing the persistent manifestations of joint pain, swelling, and stiffness. This support assists patients during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods.

The medication is also relevant for easing acute or disruptive symptom patterns associated with various musculoskeletal disorders, such as general low back pain (lumbago), sprains, and strains. Furthermore, it may be part of symptomatic management in localized inflammatory scenarios, including odontalgia and certain gynaecological conditions. Applied in clinical settings where short-term symptomatic assistance is needed, this medicine provides supportive relief when symptoms interfere with routine activities during recurrent or episodic manifestations.

Quick Fact: Relief for Inflammatory Pain
Cenital is applied in settings where symptoms are driven by inflammatory or irritative states and where short-term symptom stabilization is important.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cenital?

The population eligibility for Cenital (Aceclofenac) is strictly governed by official regulatory documentation, defining specific groups who can or must not use the medicine.

Eligibility Scope

Cenital is indicated for use in adults but is not recommended for the pediatric population (under 18 years) due to insufficient clinical data. Use in the elderly requires caution, often limiting treatment to the lowest effective dose for the shortest duration necessary.

Contraindications and Restrictions

Classification Exclusion/Restriction
Contraindicated Hypersensitivity to Aceclofenac or other NSAIDs (e.g., aspirin), severe hepatic or renal failure, active or recurrent gastrointestinal bleeding/ulcers, and established cardiovascular diseases (NYHA II–IV heart failure, ischaemic heart, peripheral arterial, or cerebrovascular disease).
Not Recommended The medicine is contraindicated during the last trimester of pregnancy and is not recommended for women who are breastfeeding or actively attempting to conceive.
Conditional Use Patients with mild to moderate hepatic impairment are eligible but are restricted to a reduced initial daily dose and must be kept under close medical surveillance.

Resulting Eligibility Structure

Official regulatory documents define eligibility by establishing clear absolute contraindications linked to severe organ function and cardiovascular status. They further establish use limitations by explicitly declaring when the drug is not recommended, primarily for children and women during specific physiological states. This framework structures eligibility based on specific, regulator-identified population risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cenital (Aceclofenac) has several officially documented interaction patterns that are consistently noted across regulatory prescribing information, structured primarily around enhanced risk and alteration of plasma concentrations of co-administered agents.

Contraindicated Combinations and Administration Constraints

Regulatory documents advise avoiding concomitant use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, due to an increased risk of adverse effects. Furthermore, the medicine is not to be used for 8–12 days following the administration of Mifepristone as it may formally reduce Mifepristone's effect.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Class Official Interaction Description
Pharmacokinetic Lithium and Digoxin May increase plasma concentrations of these co-administered drugs.
Pharmacodynamic Anticoagulants (e.g., Warfarin) May enhance the activity, increasing the risk of bleeding.
Pharmacodynamic Diuretics and Anti-hypertensives May reduce the efficacy and increase the risk of nephrotoxicity.
Pharmacodynamic Systemic Corticosteroids and SSRIs Increases the documented risk of gastrointestinal ulceration or bleeding.

Other Official Constraints

Food intake reduces the rate of absorption of Cenital, although it does not alter the overall extent of exposure. Additionally, official warnings note that use in regular alcohol consumers may cause gastric bleeding. Special attention is required in the elderly population due to a documented increased risk of serious consequences from adverse reactions when taking concomitant medications.

Mechanism of Action

Cenital's mechanism operates by inhibiting the enzyme activity central to the eicosanoid cascade. The active substance, Aceclofenac, functions as a prodrug, which is converted in vivo to active metabolites that bind to and inhibit the Cyclooxygenase-2 ( COX-2) enzyme. This specific enzyme blockade interrupts the initial step of the arachidonic acid cascade, significantly reducing the synthesis of inflammatory mediators, primarily **Prostaglandin E2 ( PGE2).

The resulting reduction in PGE2 concentration leads to a physiological modulation of peripheral signaling. Prostaglandins normally sensitize nociceptors (pain-sensing neurons) and increase local vascular permeability. The drug's mechanism reduces this chemical sensitization, thereby decreasing the amplification of signal transmission. Beyond this primary action, the active metabolites influence other cellular processes, including the production of certain pro-inflammatory cytokines ( IL-1beta) and processes involved in cartilage matrix maintenance. The mechanism is dependent on inflammation-driven prostaglandin production and is limited in biological scenarios that lack significant prostaglandin involvement.

Dosage and Administration Information

How Cenital is Used: Dosing and Administration

This section outlines the standardized usage instructions for Cenital (Aceclofenac 100 mg tablets).

Administration Protocol

Instruction Domain Detail
Route of Administration Oral (by mouth).
Dosage Form 100 mg Film-coated tablets.
Adult Recommended Dosing 200 mg daily maximum, divided into two doses.
Frequency and Timing Twice daily (BID), typically one 100 mg tablet in the morning and one in the evening.
Administration Condition Tablets should be swallowed whole with water, preferably with or after food.

Use Over Time and Population Adjustments

A key principle for the use of NSAIDs is that treatment should employ the lowest effective dose for the shortest duration possible required to control symptoms, and the need for continued therapy must be periodically re-evaluated.

Specific Use Constraints

  • Tablet Handling: Cenital tablets must be swallowed whole and should not be crushed, broken, or chewed.
  • Hepatic Impairment: For patients with impaired liver function, the initial total daily dose is typically reduced to 100 mg.
  • Pediatric Population: The use of Cenital is not recommended in children and adolescents due to insufficient data regarding its use in this age group.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cenital

This overview explains the structure and key focus areas of the official research that has been conducted on Cenital (Aceclofenac). The information here is based on findings from clinical trials and studies reviewed by health regulators, focusing on what was studied and what patterns the research reports.

Evidence for Use in Chronic Inflammatory Joint Conditions

Research exploring Cenital was evaluated in chronic joint conditions relies heavily on Randomized Controlled Trials (RCTs) and systematic reviews that combine the results of multiple trials. This evidence was studied for conditions characterized by fluctuating or episodic manifestations, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS).

Research Structure for Osteoarthritis

Research on OA, often conducted during periods of increased symptom activity, studied adults and primarily monitored outcomes related to physical discomfort, using measures like pain intensity scales, and outcomes reflecting daily functioning or activity level through standardized questionnaires. Findings describe patterns observed in the studies over study periods that were commonly short-term (a few weeks). Research contributes to the broader evidence landscape, but long-term effects are not fully established by the core trials, as follow-up durations were limited.

Research Structure for Rheumatoid Arthritis and Ankylosing Spondylitis

For both RA and AS, Cenital was evaluated in research exploring short-term symptom changes, often compared against other treatments that monitor similar outcomes. Researchers monitored specific outcomes linked to inflammatory or irritative states, such as the number of tender or swollen joints, the duration of morning stiffness, and measures of spinal mobility in AS. Research highlights changes measured during the study period. However, the available data for these conditions suggests that the evidence quality varies across studies, and research often relies on comparisons to older treatments.

Evidence for Acute Pain Conditions

Research on Cenital has explored conditions associated with acute or disruptive episodes, such as general low back pain and sprains or strains. The research examined outcomes linked to inflammatory or irritative states during these acute phases. Studies monitored patient-reported outcomes describing perceived discomfort and functional changes using short-term clinical studies. The data show patterns related to changes measured in these outcomes over defined time intervals, typically one to four weeks. Research provides context but not individual predictions; the results apply only to the populations studied and do not offer insight into recurrent or chronic pain management.

Duration of Evidence: Long-Term Studies and Follow-up

A key aspect of the research is the duration over which the medicine was observed in patients. Most of the core, high-certainty RCTs for chronic conditions employed limited follow-up durations—often lasting only a few weeks to three months. This means the research provides insight into short-term changes and outcomes describing episodic or acute changes during the study period. There is limited information for long-term outcomes or how the medicine may affect a patient over many years. Long-term effects are not fully established by the primary regulatory evidence, which means understanding the sustained or durable symptomatic patterns relies more heavily on less structured, long-term observational settings.

Evidence in Specific Patient Groups

The research generally focused on a broad adult population and outcomes capturing phases of heightened symptom activity. The results apply only to the populations studied in the main RCTs. Data for certain groups remain insufficient. For instance, evidence for use in the older adult population, specific severity strata, or those with significant co-existing medical conditions, is often limited or derived from broader data rather than dedicated, focused trials. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions and patient profiles under which they were conducted.

Research Gaps and Remaining Uncertainty

Scientific reviews and regulatory assessments highlight several areas where certainty remains low or where more research is ongoing.

Researchers noted limited follow-up durations in many of the core trials. Long-term effects are not fully established. In addition, sample sizes were modest in some studies, particularly those focusing on conditions like AS, which means results apply only to the populations studied. Comparative evidence is lacking for certain treatments; trials were often conducted against treatments used in research contexts involving fluctuating or unstable symptoms. Findings were mixed in some meta-analyses. Studies monitored outcomes related to symptom intensity or variability, but evidence quality varies across studies. This evidence highlights what is known—and what is still uncertain—about the medicine's profile.

Frequently Asked Questions (FAQ)

Common questions about Cenital (FAQ)

Q: Is Cenital considered a long-term or short-term treatment?

Official instructions state that treatment should use the lowest effective dose for the shortest duration necessary to control symptoms. The need for continued therapy is described as requiring periodic re-evaluation by a professional. This approach is consistent with the general guidelines for this class of anti-inflammatory medicines to minimize potential risks.

Q: How long does it usually take for a person to notice the effects of Cenital?

According to official regulatory documents, Cenital is absorbed relatively quickly after being taken by mouth. Peak concentrations of the active substance in the bloodstream are typically reached approximately 1.25 to 3.00 hours following ingestion.

Q: How long does the active substance from Cenital typically stay in the body?

The time it takes for half of the active substance to be eliminated from the plasma (known as the elimination half-life) is approximately 4 hours. This measure describes how quickly the drug is processed by the body.

--quinazoline--

Q: What does 'How Cenital works' mean in simple terms?

Cenital is an anti-inflammatory and analgesic medicine. Its primary method of action is mainly based on preventing the body from making specific natural substances called prostaglandins, which are key chemical messengers that cause pain and inflammation. This is achieved by temporarily interfering with a natural enzyme called Cyclo-oxygenase (COX).

Q: Are the side effects of Cenital usually temporary, or do they last for the entire treatment?

Most side effects reported in official documents have been described as minor and reversible. However, the regulatory label notes that the risk for serious adverse events, particularly gastrointestinal complications, is reported as highest during the initial stages of treatment.

Q: Is it possible to have 'start-up' effects when first taking Cenital?

Official regulatory text notes that patients are at the highest risk for certain adverse reactions, particularly gastrointestinal complications, early in the course of therapy. This initial period of higher risk often occurs within the first month of treatment.

Q: Is Cenital a brand-new medication, or has it been available for a while?

Cenital (Aceclofenac) is not a new compound. It is a well-established medication that has been approved and available for medical use in many countries for decades, with initial approvals dating back to the 1990s.

Q: Is Cenital used only for severe cases of the approved condition?

Official labeling indicates that Cenital is for the symptomatic relief of pain and inflammation in the approved chronic joint conditions. The documents do not restrict its use to only the most severe cases.

Q: Does Cenital affect blood pressure or heart rate?

Regulatory text notes that fluid retention and oedema (swelling) have been reported in association with the drug’s use. Due to this potential effect on fluid balance, patients with a history of hypertension or mild heart failure are noted in the labeling as requiring precautionary monitoring.

Q: Does Cenital therapy require blood monitoring?

For all patients receiving long-term treatment with Cenital, official guidelines describe that monitoring for precautionary measures is appropriate. This typically includes checks on renal function, hepatic function (e.g., liver enzymes), and blood counts.

Q: What are the signs of an allergic reaction to Cenital?

Serious allergic reactions, though rare, are documented in the official labeling. Symptoms can include skin rash, difficulty breathing, swelling of the face and throat, severe dizziness, wheezing, and abdominal pain.

Q: Can Cenital cause feelings of fatigue or dizziness?

Dizziness is listed in official documents as a common side effect of the medicine. Fatigue (tiredness) is also listed as a less frequent adverse event reported during clinical trials.

Q: Does Cenital affect normal sleep patterns?

Official safety reports list somnolence (drowsiness) and insomnia (difficulty sleeping) as rare side effects reported during clinical trials.

Q: Can Cenital potentially cause changes in mood or emotional state?

Rare side effects reported in clinical trials include changes in emotional state, such as depression and abnormal dreaming.

Q: Is a skin rash a frequently reported side effect of Cenital?

Skin rash is classified in official documents as an uncommon side effect. This means it is reported in less than 1 out of 100 patients.

Q: What percentage of patients in studies experienced weight changes from Cenital?

Weight increase is listed in official documents as a rare side effect. This frequency classification means it was reported in less than 1 out of 1,000 patients in clinical trials.

Q: Can Cenital be taken at the same time as other prescription medications?

Cenital has several documented interactions with other medications, including blood thinners and diuretics. Due to these potential effects, caution is advised when taking concomitant medications, and specific guidance regarding timing and potential risks is typically provided by a health professional.

Q: Are there any known drug-disease interactions with Cenital?

Use is strictly contraindicated in individuals with severe failure of the heart, kidneys, or liver. For patients with mild to moderate impairment of liver function, conditional use with a reduced initial daily dose is required.

Q: How is the interaction of Cenital with blood thinners described in official labeling?

Official labeling states that the drug may enhance the activity of anticoagulants, such as warfarin. This enhancement increases the documented risk of bleeding.

Q: What information is available about taking Cenital during pregnancy?

The medicine is formally contraindicated during the last trimester of pregnancy due to risks to the fetus. Furthermore, it is not recommended for use by women who are actively attempting to conceive.

Q: Is Cenital transferred into breast milk and what are the implications?

The medicine is formally not recommended for women who are breastfeeding.

Q: What is the usual storage recommendation for Cenital?

The medicine should be stored in its original package, protected from light, and at a temperature not exceeding 25 C or 30 C. As a safety measure, it is described as needing to be kept out of the sight and reach of children.

Q: Is Cenital classified as a controlled substance?

Cenital (Aceclofenac) belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class of medicines. It is not listed in the federal or international schedules of controlled substances.

How should Cenital be stored and disposed of?

How to Store and Dispose of Cenital

Cenital (Aceclofenac tablets) must be stored strictly according to the conditions specified in official regulatory labeling to ensure product integrity and safety.

Required Storage Conditions

The medicine should be stored at temperatures below 25 C or 30 C, depending on the specific product authorization. It is mandatory to keep the tablets in their original package to provide protection from light. As a safety measure, Cenital must be stored out of the sight and reach of children.

Disposal Requirements

Any unused or expired product must be disposed of in accordance with local requirements. Due to the environmental classification of the active substance, Cenital must not be thrown into wastewater or household waste. Following official guidelines prevents release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cenital found in:

A-Z Index: